Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin

被引：0
|
作者：
Lin, Iris
Horblyuk, Ruslan
Mardekian, Jack
Park, Sang Hee
Kamble, Shital
Hamilton, Melissa
Abdulsattar, Younos
Petkun, William
Menzin, Joseph
Lip, Gregory Y.
机构：
来源：
CIRCULATION | 2016年 / 134卷
关键词：
Atrial fibrillation; Anticoagulants; Warfarin; Hemorrhage; Outcomes;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
13828
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Major bleeding risk in elderly patients age ≥ 75 years with non-valvular atrial fibrillation initiating oral anticoagulants: A 'real-world' comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Burns, Leah
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    Squibb, Bristol-Myers
    PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213
  • [22] Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation
    Choi, E. -K.
    Lee, S. R.
    Kwon, S.
    Han, K. D.
    Jung, J. H.
    Oh, S.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2986 - 2986
  • [23] Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
    Abdullah, Ahmad Salihin
    Tan, Hwee Pheng
    Mohd Saffian, Shamin
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2022, 29 (02): : 164 - 172
  • [24] Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin
    Francis, Kevin M.
    Siu, Kimberly
    Yu, Chen
    Alvrtsyan, Hasmik
    Rao, Yajing
    Walker, David R.
    Sander, Stephen D.
    Zalesak, Martin
    Miyasato, Gavin
    Sanchez, Herman
    BLOOD, 2012, 120 (21)
  • [25] Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
    Norby, Faye L.
    Bengtson, Lindsay G. S.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Chamberlain, Alanna M.
    Rapson, Ian
    Alonso, Alvaro
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [26] REAL-WORLD COMPARISON OF MAJOR BLEEDING AND ASSOCIATED COSTS AMONG ORAL ANTICOAGULANT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Qisu, Zhang
    Baser, Onur
    Vo, Lien
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 439 - 439
  • [27] Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
    Faye L. Norby
    Lindsay G.S. Bengtson
    Pamela L. Lutsey
    Lin Y. Chen
    Richard F. MacLehose
    Alanna M. Chamberlain
    Ian Rapson
    Alvaro Alonso
    BMC Cardiovascular Disorders, 17
  • [28] Value-based pricing for dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation in Germany
    Krejczy, M.
    Marx, S.
    Obermann, K.
    Wehling, M.
    Harenberg, J.
    EUROPEAN HEART JOURNAL, 2012, 33 : 815 - 815
  • [29] Value-based pricing for dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation in Germany
    Krejczy, Martin
    Marx, Svetlana
    Obermann, Konrad
    Wehling, Martin
    Harenberg, Job
    THROMBOSIS RESEARCH, 2012, 130 : S100 - S100
  • [30] Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study
    Rutherford, O. -C. W.
    Jonasson, C. J.
    Ghanima, W. G.
    Halvorsen, S. H.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1846 - 1846
12345